< Back

THORNTON & ROSS LTD SIGN LICENSING AGREEMENT FOR NOVEL PAIN RELIEF GEL

  • 19/01/2017
  • Press Release

Thornton & Ross (T&R) are pleased to announce they have entered in to a long-term licensing agreement with Futura Medical, specialists in transdermal drug technology, for their novel topical diclofenac gel, TPR100.

Under the terms of the agreement, Thornton & Ross will conduct the manufacturing scale-up of TPR100 and hold rights to manufacture, market and distribute the product in the UK for the lifetime of the product's patents, which run to at least 2028 in the UK.

TPR100, which benefits from the rapid skin permeation rates offered by Futura's proprietary DermaSys® delivery system, demonstrated statistically significant results in a 2015 clinical study comparing the product against both placebo and currently marketed products.

Dieno George, Executive Vice President of Brands at STADA, said: "Thornton & Ross is an ideal partner for Futura, with its expertise in both OTC and Rx marketing and we are very excited to bring TPR100 into our product portfolio. TPR100's topical formulation, and positive trial results achieved to date, mean that it has the potential to be a product that very successfully meets patient needs."

Barry Draude, Managing Director at T&R, said: "Thornton & Ross are always seeking innovative technology that brings real benefits to patients and consumers and Futura's TPR100 is an excellent example of this. Futura are experts in topical pain relief and we look forward to working with them and to bringing this exciting product to market"

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.